Terbinafine. An update of its use in superficial mycoses
- PMID: 10439936
- DOI: 10.2165/00003495-199958010-00018
Terbinafine. An update of its use in superficial mycoses
Abstract
Terbinafine is an allylamine antifungal agent which has fungicidal activity against a wide variety of dermatophytes, moulds and certain dimorphic fungi, and fungistatic activity against Candida albicans. Oral terbinafine 250 mg/day is effective in the treatment of superficial dermatophyte infections such as onychomycosis, tinea pedis and tinea corporis/cruris, generally achieving mycological cure in > 80% of patients. The drug is also effective in children with tinea capitis when administered orally in the dosage range 62.5 to 250 mg/day for 4 weeks. Comparative data indicate that oral terbinafine is more effective than continuous or intermittent intraconazole in dermatophyte onychomycosis, and is as effective as itraconazole 400 mg/day in tinea pedis. The drug has shown greater efficacy than griseofulvin in dermatophyte onychomycosis, tinea pedis and tinea corporis/cruris, and comparable efficacy in children with tinea capitis. Additionally, oral terbinafine is more effective than ketoconazole 200 mg/day in tinea corporis/cruris. Topical terbinafine 1% formulations are effective when applied once or twice daily for up to 2 weeks, achieving mycological cure in > 80% of patients with tinea pedis, tinea corporis/cruris, cutaneous candidiasis and pityriasis versicolor. Its formulations are at least as effective as miconazole 2% cream and naftifine 1% gel in tinea pedis, and more effective than clotrimazole 1% cream, bifonazole 1% cream and oxiconazole 1% lotion. Mycological cure rates achieved with terbinafine generally improve after treatment cessation, reflecting the drug's fungicidal mechanism of action and its residual effect in tissue. Terbinafine is well tolerated after oral or topical administration and has a relatively low potential for drug interactions. Pharmacoeconomic data support the use of terbinafine in dermatophyte infections of the skin or nails.
Conclusions: Evidence suggests that oral terbinafine is the treatment of choice for dermatophyte onychomycosis, as it achieves high rates of mycological and clinical cure, is generally well tolerated and has a relatively low potential for drug interactions. It must also be considered a first-line treatment option, along with itraconazole, in cutaneous mycoses which warrant systemic treatment; topical terbinafine is a treatment of choice in less extensive mycoses. The use of terbinafine in non-dermatophyte or mixed infections has not been fully defined.
Similar articles
-
Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.Drugs. 1992 Feb;43(2):259-84. doi: 10.2165/00003495-199243020-00010. Drugs. 1992. PMID: 1372222 Review.
-
Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.Drugs. 2009;69(3):339-59. doi: 10.2165/00003495-200969030-00009. Drugs. 2009. PMID: 19275277 Review.
-
Topical antifungal treatments for tinea cruris and tinea corporis.Cochrane Database Syst Rev. 2014 Aug 4;2014(8):CD009992. doi: 10.1002/14651858.CD009992.pub2. Cochrane Database Syst Rev. 2014. PMID: 25090020 Free PMC article. Review.
-
Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.Pharmacoeconomics. 1995 Sep;8(3):253-69. doi: 10.2165/00019053-199508030-00008. Pharmacoeconomics. 1995. PMID: 10155621 Review.
-
Clinical efficacy and tolerability of terbinafine (Lamisil)--a new topical and systemic fungicidal drug for treatment of dermatomycoses.Clin Exp Dermatol. 1989 Mar;14(2):124-7. doi: 10.1111/j.1365-2230.1989.tb00908.x. Clin Exp Dermatol. 1989. PMID: 2689015 Clinical Trial.
Cited by
-
Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics.J Clin Aesthet Dermatol. 2024 Mar;17(3):24-33. J Clin Aesthet Dermatol. 2024. PMID: 38495549 Free PMC article. Review.
-
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.J Antimicrob Chemother. 2022 Jul 28;77(8):2053-2073. doi: 10.1093/jac/dkac161. J Antimicrob Chemother. 2022. PMID: 35703391 Free PMC article. Review.
-
Chromatin Structure and Drug Resistance in Candida spp.J Fungi (Basel). 2020 Jul 30;6(3):121. doi: 10.3390/jof6030121. J Fungi (Basel). 2020. PMID: 32751495 Free PMC article. Review.
-
Evaluation of Association Between Oral and Topical Terbinafine Use in Pregnancy and Risk of Major Malformations and Spontaneous Abortion.JAMA Dermatol. 2020 Apr 1;156(4):375-383. doi: 10.1001/jamadermatol.2020.0142. JAMA Dermatol. 2020. PMID: 32129793 Free PMC article.
-
Preparation, Characterisation, and Topical Delivery of Terbinafine.Pharmaceutics. 2019 Oct 22;11(10):548. doi: 10.3390/pharmaceutics11100548. Pharmaceutics. 2019. PMID: 31652587 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources